Novo rival beats expectations
Source ↗
👁 0
💬 0
The market for obesity treatments continues to exceed expectations, as Eli Lilly outperformed analyst predictions in the first quarter. The company reported revenue of $19.8 billion, a 56 percent increase compared to the same period last year. This growth occurred despite price reductions for the obesity and diabetes medications Mounjaro and Zepbound, with Mounjaro sales […]
Comments (0)